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Abstract
Background: Type 2 diabetes mellitus (T2DM) has been suggested to increase the risk of cancers. The aim of this
study was to investigate the risk of common cancers in Chinese patients with T2DM.
Methods: A population-based retrospective cohort study including 36,379 T2DM patients was conducted in
Minhang District of Shanghai, China, during 2004 to 2010. All T2DM patients were enrolled from the standardized
management system based on local electronic information system. Newly-diagnosed cancer cases were identified
by record-linkage with the Shanghai Cancer Registry. Standardized incidence ratios (SIR) and 95 % confidence
interval (CI) were used to estimate the risk of cancers among T2DM patients.
Results: Overall crude incidence rate (CIR) of cancers was 955.21 per 105 person-years in men and 829.57 per 105
person-years in women. Increased risk of cancer was found in both gender, with an SIR being 1.28 (95 % CI = 1.17–1.38)
in men and 1.44 (95 % CI =1.32–1.55) in women. Increased risk of colon (SIR = 1.97; 95 % CI = 1.49 to 2.46), rectum (1.72;
1.23 to 2.21), prostate (2.87; 2.19 to 3.56), and bladder cancers (1.98, 1.28 to 2.68) were observed in men and elevated risk
of colon (1.67; 1.25 to 2.08), breast (1.66; 1.38 to 1.95), and corpus uteri cancers (2.87; 2.03 to 3.71) were observed in
women.
Conclusions: Our results indicate that Chinese patients with T2DM may have an increased risk of some cancers, and the
increase may vary by sub-sites of cancers.
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Background
Type 2 diabetes mellitus (T2DM) is one of the major
public health problems around the world. Over past
decades, the prevalence of T2DM has been increasing
rapidly in Asian populations [1]. In China, the preva-
lence of diabetes and pre-diabetes reached 9.7 and
15.5 %, respectively, in adults at age of 20 years or above
in 2008, which means that 92 million Chinese adults
were with diabetes and 148 million with pre-diabetes in
the country [2].
Epidemiologic evidence is accumulating on the associ-
ation between T2DM and cancers, particularly for
cancers of colorectum [3–5], liver [6, 7], breast [8, 9],
bladder [10], kidney [11], and prostate [12]. However,
the results are not consistent [13–17], and the associations
differ by race and ethnicity [18]. To elucidate the associa-
tions of T2DM with the risk of cancers is particularly im-
portant in China, because, with the huge population and
high prevalence of T2DM, even a small increase in the
cancer risk might have a significant public health impact
at the population level for the country.
The present study was specifically designed to reveal
the possible associations of T2DM with overall and
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Based on the Chinese National Diabetes Prevention
Guide, standardized management for diabetes patients,
as a basic community health service, has been carried
out since 2004 in Minhang district, an administrative
division with 1,000,000 residents of Shanghai, China.
The patients enrolled in the management system in-
cluded: 1) part of prevalent T2DM patients; 2) newly-
diagnosed T2DM patients from local comprehensive
hospitals, 3) newly-diagnosed T2DM patients from regu-
lar health check-up programs for all local residents over
60 years provided by community health service centers
(CHSC), and 4) newly-diagnosed T2DM patients from
free screening for high risk group with specific symp-
toms or claims provided by CHSC. Due to that the
T2DM patients diagnosed in hospitals out of Minhang
district were not routinely enrolled for standardized
management, most T2DM patients registered in the
system were from local hospitals, which accounted for
about 90 % of all newly-diagnosed patients in local
hospitals each year.
The standardized management referred to regular
following-up of patients carried out by General Practi-
tioners. According to the Chinese National Diabetes Pre-
vention Guide, the frequency of following-up and health
care service provided to the patients were determined
and standardized according to the patient’s clinical condi-
tions. The patients with fasting blood glucose < 7.0 mmol/L
were followed up every 3 months by measuring blood pres-
sure and testing levels of blood glucose, glycosylated
hemoglobin and urine protein, and the patients with fasting
glucose > 7.0 mmol/L were followed up once per month.
During the 7-year period from 2004 to 2010, a total of
36,379 diabetes patients were enrolled and followed-up. All
these data was recorded as electronic health records (eHR)
and transmitted into the eHR database. Using the unique
identification card number of each individual, the incident
cancer cases were identified through record-linkage of eHR
system with Cancer Registry System in Minhang district,
which is part of the Shanghai Cancer Registry system
[19, 20]. The ICD-10 codes were assigned to each can-
cer case by the type of cancers such as Stomach (C16),
Colon (C18), Rectum (C19-C20), Liver (C22), Pancreas
(C25),Trachea / bronchus and lung (C33-C34), Brain/
central nervous system (C70-72), Prostate (C61), Kidney
(C64), Bladder (C67), Breast (C50), Corpus uteri (C53)
and Thyroid (C73).
Datum of all subjects was acquired based on local
basic community health service. Verbal informed consent
was obtained from all these enrolled patients. Ethics
approval was granted from the Institutional Review Board
of Minhang Center for Disease Control and Prevention
(NO: EC-P-2012-002).
Statistical analysis
Person-years (PY) of follow-up were calculated from the
date that T2DM was first diagnosed to the date on
which common cancer was diagnosed, or death date, or
the December 31, 2010, whichever occurred first. Crude
incidence rate (CIR) for cancers was calculated by the
number of incident cancer cases divided by the number
of observed person-years. The age-standardized rate
(ASR [W]) was calculated using the World Standard
Population.
The standardized incidence ratio (SIR) and its 95 %
confident interval (95 % CI) were used to estimate the
risk of common cancer in patients with T2DM. SIRs of
cancers were determined by comparing the observed and
expected number of cancer cases among T2DM patients,
in which the latter was calculated by applying the age-
specific incidence rates in the general population.
SIR ¼ the number of observed cancer cases
the number of expected cancer cases
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U test based on Poisson distribution was applied to
compare the CIRs of cancers between prevalent and







X1 and X2 represent the number of cancer cases in
prevalent and newly-diagnosed T2DM patients, and n1
and n2 represent person-years of observation for preva-
lent and newly-diagnosed T2DM patients, respectively.
All tests were two sided. P value less than 0.05 was
considered as statistical significant.
Results
Between Jan 1, 2004 and Oct 31, 2010, 36,379 T2DM pa-
tients were enrolled and followed-up regularly through
eHR system in Minhang district of Shanghai, China. The
characteristics of the T2DM patients are shown in Table 1.
Of the 36,379 T2DM patients, 16,166 (44.4 %) were men
and 20,213 (55.6 %) were women, with mean age being
58.44 and 59.37 years, respectively. After 136,187 person-
years of following-up, 1205 cancer cases were identified
through record-linkage of eHR system with the Cancer
Registry System. The overall crude incidence rate (CIR) of
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cancers was 955.21 per 105 person-years in men and
829.57 per 105 person-years in women, with ASR (W) be-
ing 289.69 and 246.22 per 105 person-years, respectively.
The top ten cancer subtypes by CIR were Stomach, Colon,
Rectum, Liver, Pancreas, Trachea, bronchus and lung,
Brain, central nervous system, Prostate, Bladder, and
Kidney cancer in men, and were Stomach, Colon, Rectum,
Liver, Pancreas, Trachea/bronchus and lung, Brain, central
nervous system, Breast, Corpus uteri, and Thyroid cancer
in women, as shown in Table 2.
SIRs of common cancers in T2DM patients by gender
and subtypes of cancers are shown in Table 3. An
increased risk of overall cancer in T2DM patients
were found in both men and women, with SIRs of
1.28 (95 % CI: 1.17–1.38) and 1.44 (95 % CI: 1.32–1.55),
respectively. For subtypes of cancer, a significant increased
risk of colon (1.97; 1.49 to 2.46), rectum (1.72; 1.23 to
2.21), prostate (2.87; 2.19 to 3.56), and bladder cancers
(1.98, 1.28 to 2.68) was observed in men and elevated risk
of colon (1.67; 1.25 to 2.08), breast (1.66; 1.38 to 1.95) and
corpus uteri cancers (2.87; 2.03 to 3.71) was observed in
women. We did not find a significant association between
T2DM and Stomach, Liver, Pancreas, Brain, Kidney
cancers.
The risk of cancers was not observed to increase in
patients at all age groups. In men, an increased risk
was found in patients at ages of 70- and 80- years,
with SIRs of 1. 54 (95 % CI: 1.34–1.73) and 2.79
(95 % CI: 2.17–3.42), respectively. In women, an in-
creased risk was also observed in older patients, with
Table 1 Baseline description of the diabetes cohort
Variable Men (N = 16166) Women (N = 20213)
Follow-up time (Median, years) 3.70 Range: 1–7 3.78 Range: 1–7
Age (mean, years) 58.44 Range: 21–94 59.37 Range: 21–95
Calendar year of enrolment (N, %)
2004 755 4.67 978 4.84
2005 514 3.18 689 3.41
2006 2832 17.52 3940 19.49
2007 4469 27.64 5563 27.52
2008 5303 32.80 6532 32.32
2009 2009 12.43 2253 11.15
2010 284 1.76 258 1.28
Table 2 CIRs and ASRs of cancers in patients with T2DM
Men (N = 16166) Women (N = 20213)
Subtypes No. of cancer cases CIRa ASRb (world) No. of cancer cases CIR ASR (world)
Stomach 74 123.58 35.22 49 64.22 14.88
Colon 63 105.21 34.91 63 82.56 19.24
Rectum 48 80.16 21.49 30 39.32 10.09
Liver 51 85.17 23.43 24 31.45 10.25
Pancreas 24 40.08 11.94 18 23.59 6.20
Trachea, bronchus and lung 62 103.54 26.12 56 73.39 18.59
Brain, central nervous system 9 15.03 4.11 24 31.45 7.93
Prostate 68 113.56 35.93
Kidney 16 26.72 7.36 9 11.79 5.43
Bladder 31 51.77 16.84
Breast 132 172.99 53.40
Corpus uteri 45 58.97 24.74
Thyroid 3 5.01 1.77 26 34.07 19.56
Others 123 205.40 70.57 157 205.76 55.91
Total 572 955.21 289.69 633 829.57 246.22
aCIR: crude incidence rate (per 100000 person years)
bASR: Age-standardized rate (per 100000 person years) calculated using World Standard Population data
Xu et al. BMC Cancer  (2015) 15:852 Page 3 of 8
SIRs being 1.48 (95 % CI: 1.28–1.69) in patients at
ages of 60- years, 1.79 (95 % CI: 1.56–2.03) in patients at
ages of 70- years, and 2.20 (95 % CI: 1.61–2.78) in patients
at ages of 80- years, respectively (as shown in Table 4).
In this study, we did not find a significant difference in
age distribution between prevalent and newly-
diagnoseddiabetes patients. However, the risk of cancers
was significantly higher in prevalent diabetes patients
(CIR = 494.37 per 105 person-years) than in those
newly-diagnosed (CIR = 991.04 per 105 person-years).
The difference was significant in both men (U = 5.06,
P < 0.05) and women (U = 8.75, P < 0.05) (as shown in
Table 5).
Discussion
The association between T2DM and the risk of common
cancers has been extensively investigated in western
countries. In China, however, only a few studies have
been focused on the associations, and the findings were
not consistent [15, 16]. In this study, based on local
population-based registry data, we observed an increased
risk of overall cancer in Chinese with T2DM. Our results
are consistent with Wideroff et al’s report [13], in which
diabetic patients in Denmark was found having 10 % in-
creased risk of all types of cancers (SIR = 1.1). However,
no significant association was found between T2DM and
an incidence of cancer (RR = 0.99, 95 % CI = 0.90–1.09)
in a UK study [17]. Ethnic discrepancy on biologic effect
of T2DM may partly explain the inconsistency [18].
Moreover, due to the fact that the risks of cancers in dia-
betes patients may vary by sub-sites of cancers and the
ranks of cancers differ across populations, it is necessary
to compare the associations of T2DM with the risk of
site-specific cancers in different populations.
One of the main findings in previous studies is that
diabetes patients have an increased risk of colorectal
Table 3 SIRs of cancers in patients with type 2 diabetes by gender and subtype of disease
Male (N = 16166) Female (N = 20213)
No. of cancer cases SIR 95 % CI No. of cancer cases SIR 95 % CI
Observed Expected Low Upper Observed Expected Low Upper
Stomach 74 63.5 1.17 0.90 1.43 49 39.0 1.26 0.91 1.61
Colon 63 31.9 1.97 1.49 2.46 63 37.8 1.67 1.25 2.08
Rectum 48 27.9 1.72 1.23 2.21 30 23.5 1.28 0.82 1.73
Liver 51 42.5 1.20 0.87 1.53 24 22.0 1.09 0.65 1.53
Pancreas 24 18.7 1.28 0.77 1.80 18 18.8 0.96 0.51 1.40
lung 62 103.3 0.60 0.45 0.75 56 53.9 1.04 0.77 1.31
Brain 9 9.9 0.91 0.32 1.51 24 16.2 1.48 0.89 2.07
Prostate 68 23.7 2.87 2.19 3.56
Kidney 16 10.9 1.47 0.75 2.19 9 6.3 1.42 0.49 2.35
Bladder 31 15.6 1.98 1.28 2.68
Breast 132 79.4 1.66 1.38 1.95
Corpus uteri 45 15.7 2.87 2.03 3.71
Thyroid 3 4.2 0.71 0.09 1.51 26 20.2 1.29 0.79 1.79
Others 117 95.8 1.22 1.00 1.44 157 107.8 1.46 1.23 1.68
Total 572 447.9 1.28 1.17 1.38 633 440.7 1.44 1.32 1.55
Table 4 CIRs and SIRs of cancer in T2DM patients by age group
Age groups Men Women
No. of cancer cases SIR 95 % CI No. of cancer cases SIR 95 % CI
Observed Expected Low Upper Observed Expected Low Upper
30- 2 1.6 1.25 0.48 2.98 6 3.3 1.82 0.36 3.27
40- 16 23.0 0.70 0.35 1.04 34 39.0 0.87 0.58 1.16
50- 93 85.2 1.09 0.87 1.31 112 111.9 1.00 0.82 1.19
60- 142 152.8 0.93 0.78 1.08 204 137.4 1.48 1.28 1.69
70- 243 158.0 1.54 1.34 1.73 223 124.4 1.79 1.56 2.03
80- 76 27.2 2.79 2.17 3.42 54 24.6 2.20 1.61 2.78
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cancer [17, 21, 22]. However, the increases in risk of
colon and rectum cancers were found much different.
Ren, et al. [23] reported a significant increased risk of
colon cancer in male T2DM patients and a borderline
significant risk of colon cancer in females, and did not
find a significant association between T2DM and risk of
rectal cancer in both sexes. The results in this study are
sometime inconsistent with Ren, et al’s report. Our pa-
tients, both male and female, were more likely to have
colon cancer. The increase in the risk of rectum cancer
was also observed in both sexes, but the association
reached significant only in male patients.
Our finding of an elevated risk of prostate cancer in
male T2DM patients is consistent with the results re-
ported by Tseng, et al. [24] and Will, et al. [25], but is
not in line with some other studies. Evidence has been
available for the null [26] and inverse associations be-
tween T2DM and prostate cancer [27, 28]. The result
from a meta-analysis indicates that diabetes was associ-
ated with an increased risk of prostate cancer in Asians
but the RR was greatly attenuated by adjusting for some
confounders (unadjusted RR = 2.82, adjusted RR = 1.31)
[29]. The mechanism underlying the association is un-
clear. It is possible that the difference in exposures to
common risk factors such as tobacco smoking, obesity,
and some psychology factors [30] and difference in
genetic background [31–33] may contribute to the in-
consistency. Moreover, average level of PSA was signifi-
cantly lower in diabetes patients than in non-diabetes, as
were as frequency of PSA screening [34], which may
partly explain the inverse association between T2DM
and prostate cancer.
For other types of cancers, we observed higher risks of
breast and Corpus uteri cancers in females and bladder
cancer in males, which is consistent with previous stud-
ies [15, 16]. A significant inverse association between
diabetes and lung cancer was observed in men, which is
also consistent with previous studies [16]. However, we
did not find a significant association of T2DM with the
risk of pancreatic and kidney cancers, which is not con-
sistent with the positive association reported in several
studies [35, 36]. Inadequate statistical power due to
small sample size may explain the results on rare can-
cers. Moreover, we did not take some potential con-
founders into consideration such as sedentary lifestyle,
tobacco smoking and obesity, the shared risk factors of
T2DM and certain cancers [37]. More studies are
needed to distinguish the effect of diabetes from those of
shared risk factors and diabetes management.
Many biological mechanisms may be involved in the
elevated risks of overall or certain sub-sites cancers
among T2DM patients. Usually, diabetic patients have
hyperinsulinemia and are associated with reduced insu-
lin sensitivity and compensatory hyperinsulinemia as
well as an increased insulin-like growth factor (IGF)-1
level, which may stimulate cell proliferation in pancreas,
colon, breast, and other organs. Insulin itself exerts a
mitogenic effect on various tissues including breast can-
cer cell lines, which are usually oestrogen receptor posi-
tive [38]. In breast cancer, insulin induces aromatase
activity and reduces sex hormone binding globulin
(SHBG), leading to increased free oestrogen levels,
which in turn increases mitogenicity [39]. Interestingly,
breast cancer cells appear to have high levels of insulin
receptors, compared to normal breast tissue [40]. Insulin
may exert a mitogenic effect through insulin-like growth
factor-1 (IGF-1) receptors. Prospective studies have
shown that people with circulating IGF-1 have an in-
creased risk of common epithelial cancers such as
breast, colon and prostate cancer [41]. A recent large
population based survey showed that women with high
blood concentrations of IGF-1 are more likely to develop
breast cancer, women with the highest concentration of
IGF-1 were found to have a 28 % higher risk of develop-
ing breast cancer than women with the lowest concen-
tration [OR 1.28 (95 % CI 1.14–1.44)] [42]. The direct
link between diabetes and cancer through hyperinsuline-
mia, hyperglycemia and inflammation may explain the
high risk of cancers in prevalent T2DM patients than in
those newly-diagnosed. It has been suggested that
duration of diabetes and use of exogenous insulin
were associated with the cancer risk [30]. It seems that
long-term exposure to insulin has direct relevance to the
cancer risk.
Strengths and limitations
The strengths of this study included its prospective
study design, representative and relative large sample
size of diabetes patients, confirmation system of diagno-
sis and high quality cancer registry system, which pro-
vide us a good opportunity to evaluate the possible
effect of T2DM on cancer risk in Chinese population.
Several limitations of the study should be mentioned.
First, the small number of some site-specific cancers
may lead to a low statistical power to detect a significant
association. Therefore, we only focused on the top ten
subtypes of cancers to ensure statistical power. Second,
the average following-up time was rather short for many
patients, which also may influence the statistical power.
Moreover, due to the number of patients screened varied
year by year, it is possible that the patients recruited in
certain years were detected earlier while those in other
years were not, which may lead to heterogeneity of the
patient population. Third, although age and gender were
controlled in calculation of SIR, we did not obtain and
adjust other risk factors such as smoking, alcohol con-
sumption, body mass index (BMI), physical activity and
use of antidiabetic medicines, in which use of
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antidiabetic drug metformin has been associated with re-
duced risk of cancers [36] and BMI was reported to be
associated with increased risk of both of T2DM and can-
cers [37]. Finally, diabetes is an under-diagnosed disease
and some T2DM patients remained undiagnosed, which
may lead to misclassification bias.
Conclusion
In summary, the present study suggested that type 2 dia-
betes may increase the risks of overall cancers, particu-
larly in older patients and prevalent patients. Diabetes is
associated with an increased risk some cancers (colon,
rectum, prostate, and bladder cancers in men and colon,
breast, and corpus uteri cancers in women), and related
with a reduced risk of lung cancer in men. For some
other cancer sites, there appears to be no association
possibly due to inadequate statistics power.
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